Development of chronic cutaneous lupus erythematosus during biologic therapy: A systematic review

J Am Acad Dermatol. 2021 Mar;84(3):835-838. doi: 10.1016/j.jaad.2020.09.087. Epub 2020 Oct 3.

Authors

Sara Mirali¹, Asfandyar Mufti², Rafael Paolo Lansang³, Muskaan Sachdeva¹, Jensen Yeung⁴

Affiliations

¹ Faculty of Medicine, University of Toronto, Canada.
² Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada.
³ Faculty of Health Sciences, McMaster University, Hamilton, Canada.
⁴ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Women's College Hospital, Toronto, Ontario, Canada; Probity Medical Research Inc, Waterloo, Ontario, Canada. Electronic address: jensen.yeung@utoronto.ca.

PMID: 33022308
DOI: 10.1016/j.jaad.2020.09.087

No abstract available

Publication types

Letter
Systematic Review

MeSH terms

Anti-Inflammatory Agents / adverse effects*
Arthritis, Rheumatoid / drug therapy
Arthritis, Rheumatoid / immunology
Biological Products / adverse effects*
Humans
Lupus Erythematosus, Discoid / chemically induced
Lupus Erythematosus, Discoid / epidemiology*
Lupus Erythematosus, Discoid / immunology
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / drug therapy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / immunology
Psoriasis / drug therapy
Psoriasis / immunology
Spondylitis, Ankylosing / drug therapy
Spondylitis, Ankylosing / immunology
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Tumor Necrosis Factor-alpha / immunology

Substances

Anti-Inflammatory Agents
Biological Products
TNF protein, human
Tumor Necrosis Factor-alpha